More accountable care organizations are taking on downside financial risk in the Medicare Shared Savings Program than ever before, with 37% in the program today participating in these arrangements.

The world could soon have a new most expensive drug if an experimental gene therapy for hemophilia patients could come in with a price tag between $2 million and $3 million is approved.

The Centers for Medicare & Medicaid Innovation savings projections keep moving, underscoring just how difficult it is to estimate the impact of untested alternative payment models, according to a recent analysis from Avalere Health.

Changing models across hospitals and health systems helped drive mergers and acquisition activity in 2019, according to a new report from Kaufman Hall.

The innovation and venture capital arm of University of Pittsburgh Medical Center (UPMC) is planning to invest $1 billion into life sciences to develop new drugs, diagnostics and devices over the next four years.

Executives in the healthcare space are expecting more M&A activity in 2020 compared to 2019, according to a new outlook from KPMG. 

New medical treatments such as gene therapies come with a high price tag up to six figures, and drugmakers are working hard to ensure they can get reimbursed for these medicines in creative ways.

Global venture capital funding in digital health dropped 6% in 2019, with 615 deals nabbing $8.9 billion in capital.

Virtual care provider Teledoc Health will acquire InTouch Health for the purchase price of $600M.

Accountable care organizations are increasingly saving Medicare more money, but after the Trump administration made significant changes to the Medicare Shared Savings Program, fewer of these organizations are participating, according to data from the National Association of Accountable Care Organizations (NAACOS).

Drug prices are still rising, with manufacturers hiking up prices at the start of 2020. And the “reluctance” from the Republican party to challenge those rising prices could become a huge liability for the upcoming 2020 election, according to The Hill.

Drug prices are still rising in 2020, but the rate of inflation appears to be slowing down. For investors, however, that might be good news, according to The Wall Street Journal.